GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Beneish M-Score

Hemagen Diagnostics (Hemagen Diagnostics) Beneish M-Score : 0.00 (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Hemagen Diagnostics's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Hemagen Diagnostics was 0.00. The lowest was 0.00. And the median was 0.00.


Hemagen Diagnostics Beneish M-Score Historical Data

The historical data trend for Hemagen Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Beneish M-Score Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -3.92 -2.83 -3.77 -3.46

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.77 -3.54 -3.29 -4.19 -3.46

Competitive Comparison of Hemagen Diagnostics's Beneish M-Score

For the Biotechnology subindustry, Hemagen Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Beneish M-Score falls into.



Hemagen Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hemagen Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2163+0.528 * 0.9562+0.404 * 1.5004+0.892 * 0.7861+0.115 * 0.8794
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.051+4.679 * -0.224724-0.327 * 1.272
=-3.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep12) TTM:Last Year (Sep11) TTM:
Total Receivables was $0.59 Mil.
Revenue was 0.876 + 0.948 + 1.111 + 1.107 = $4.04 Mil.
Gross Profit was 0.402 + 0.453 + 0.351 + 0.407 = $1.61 Mil.
Total Current Assets was $2.10 Mil.
Total Assets was $2.44 Mil.
Property, Plant and Equipment(Net PPE) was $0.28 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.17 Mil.
Selling, General, & Admin. Expense(SGA) was $2.01 Mil.
Total Current Liabilities was $1.95 Mil.
Long-Term Debt & Capital Lease Obligation was $4.05 Mil.
Net Income was -0.163 + -0.132 + -0.244 + -0.369 = $-0.91 Mil.
Non Operating Income was 0.001 + 0 + -0.001 + 0 = $0.00 Mil.
Cash Flow from Operations was -0.051 + 0.017 + -0.117 + -0.208 = $-0.36 Mil.
Total Receivables was $0.62 Mil.
Revenue was 1.146 + 1.401 + 1.218 + 1.377 = $5.14 Mil.
Gross Profit was 0.468 + 0.668 + 0.316 + 0.51 = $1.96 Mil.
Total Current Assets was $2.45 Mil.
Total Assets was $2.89 Mil.
Property, Plant and Equipment(Net PPE) was $0.39 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.19 Mil.
Selling, General, & Admin. Expense(SGA) was $2.43 Mil.
Total Current Liabilities was $1.53 Mil.
Long-Term Debt & Capital Lease Obligation was $4.05 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.588 / 4.042) / (0.615 / 5.142)
=0.145473 / 0.119603
=1.2163

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.962 / 5.142) / (1.613 / 4.042)
=0.381564 / 0.39906
=0.9562

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.095 + 0.282) / 2.443) / (1 - (2.449 + 0.387) / 2.888)
=0.027016 / 0.018006
=1.5004

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.042 / 5.142
=0.7861

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.186 / (0.186 + 0.387)) / (0.165 / (0.165 + 0.282))
=0.324607 / 0.369128
=0.8794

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.006 / 4.042) / (2.428 / 5.142)
=0.496289 / 0.47219
=1.051

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.05 + 1.95) / 2.443) / ((4.05 + 1.526) / 2.888)
=2.455997 / 1.930748
=1.272

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.908 - 0 - -0.359) / 2.443
=-0.224724

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hemagen Diagnostics has a M-score of -3.46 suggests that the company is unlikely to be a manipulator.


Hemagen Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines